RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

Trial Profile

RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Breast cancer
  • Focus Pharmacodynamics
  • Acronyms RAPANK
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 04 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top